Revolutionising wound care with biomimicry and evidence-based medicine
Joined May 2021
- Tweets 117
- Following 189
- Followers 62
- Likes 7
112 Photos and videos
Jun 10
25–40% of hospital beds are occupied by patients with chronic wounds.
That's not a footnote. That's a system in crisis and ~100 million people living with the consequences.
Learn more at solascure.com.
#WoundCare #ChronicWounds #HealthcareInnovation #SolasCure
1
May 11
Aurase Wound Gel has demonstrated an excellent safety and tolerability profile: no underlying treatment-related safety or local tolerability issues at 24 U/mL, no need for anesthesia or analgesia, and no additional pain vs standard of care.
#PatientReportedOutcome
26
Apr 22
In chronic wound drug development, hard data separates an “interesting signal” from a de-risked mechanism.
In SolasCure’s latest Phase 2 study, Aurase Wound Gel showed a strong correlation between 4-week slough reduction & wound area reduction (r=0.7552, p=0.0072).
#WoundCare
8
Apr 14
In its latest Phase II clinical trial, Aurase Wound Gel has delivered consistent, highly significant improvements in both debridement and healing versus control.
#ClinicalData #Phase2 #AuraseWoundGel #SolasCure #Efficacy #WoundHealing #Debridement
4
Mar 27
Aurase Wound Gel has demonstrated an excellent safety and tolerability profile: no underlying treatment-related safety or local tolerability issues at 24 U/mL, no need for anesthesia or analgesia, and no additional pain vs standard care.
#SafetyProfile #AuraseWoundGel
5
Mar 18
Aurase Wound Gel works through two simultaneous mechanisms of action: continuous enzymatic debridement and active PAR2-mediated healing.
The result is a continuously clean, physiologically optimal wound bed that is actively stimulated to heal, rather than passively maintained.
3
Mar 14
Aurase Wound Gel (AWG) is SolasCure’s Phase 2 biologic designed to be the first-line therapy for both debridement and healing across chronic wounds.
For investors, that is not just a better product — it is a mechanistic paradigm shift in wound care.
#AuraseWoundGel #Biotech
3
Mar 13
Aurase Wound Gel (AWG) is SolasCure’s Phase 2 biologic designed to be the first-line therapy for both debridement and healing across chronic wounds.
For investors, that is not just a better product — it is a mechanistic paradigm shift in wound care.
#BiologicTherapy #Biotech
5
Mar 9
SANTYL, the current enzymatic incumbent, debrides slowly and has limited impact on time to closure.
The market is telling a clear story: better debridement is not enough — the next generation must debride and heal.
#Debridement #WoundHealing #StandardOfCare #BiotechInnovation
9
Mar 4
Around ~5 million Americans live with chronic, non-healing wounds, costing the healthcare system over $25 billion every year.
SolasCure was founded to change that equation with a dual-action biologic that both debrides and heals wounds.
#ChronicWounds #WoundCare
13
2 Nov 2023
NEWS: SolasCure is delighted to announce that it has been selected to receive the European Innovation Council’s @EUeic Accelerator Grant to continue development of its innovative wound care technology.
Read more: bit.ly/3FGZLnH
#woundcare #chronicwounds #EIC
3
6
656
5 Apr 2023
SolasCure welcome Lee Harle as our Chief Business Officer, responsible for spearheading our market-entry strategy.
Lee brings 25 years’ experience building successful businesses & joint-ventures in consumer goods, technology & life-science industries worldwide.
1
3
287
27 Mar 2023
SolasCure announces £10.9m Series B fundraise to advance #woundcare innovation.
The funding supports development of Aurase Wound Gel, progressing clinical trials of this innovative wound debriding enzyme following completion of the Phase IIa safety study: bit.ly/3KbFQ3q
94
14 Feb 2023
SolasCure are delighted to be named a top Biopharma companies in Cambridgeshire.
SolasCure’s pioneering aim to develop efficacious wound care products by leveraging maggot enzyme earned a place, alongside the likes of Astra Zeneca & Healx.
#woundcare
bit.ly/3YrF4Ed
53
3 Feb 2023
SolasCure are delighted to have been selected as a UK Life Sciences Innovator 2023. This is significant recognition by @tradegovukMEAP of our propriety technology as we work to develop revolutionary wound care treatments.
#LSI2023 #UKInnovation #LifeSciences #Future #Technology
1
72
2 Feb 2023
SolasCure is delighted to announce that CTO Dr Bela Kelety will be speaking at this year’s Pharma Contract Manufacturing conference in Berlin from 28th -30th March, sharing insights on the importance of scaling up for start-ups.
@PharmaIQ
#pharmaevents #PCM2023 #biotech
1
121
19 Jan 2023
We are delighted that David Fairlamb, Director of Regulatory Affairs at SolasCure, has won the Futures category at the TOPRA awards, which recognises the role of regulatory scientists in realising the potential of cutting-edge technologies.
Learn more: bit.ly/3XAKxYt
31
17 Jan 2023
SolasCure's toxicology & pre-clinical research programme has been published in the International Wound Journal, with the enzyme used in Aurase Wound Gel shown to have a good safety profile.
Read more: bit.ly/3w9qnJy
#woundcare #IWJ #chronicwounds
1
2
54
1 Dec 2022
Meet Oliver Schofield, Chief Financial Officer at SolasCure. Oliver is an experienced biotech start-up CFO & previously worked in management consulting at KPMG. He is also CIMA certified.
Read more about wound care problems SolasCure is looking to solve: solascure.com
21 Nov 2022
We're delighted to announce that David Fairlamb, Director of Regulatory Affairs at SolasCure, has won the Futures category at the TOPRA awards, recognising the role of regulatory scientists in realising the potential of cutting-edge technologies.
Read on: bit.ly/3DSjjnK
1